Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2638-2645

  Louie, Arnold ^a   Bied, Adam ^b   Fregeau, Christine ^a   Van Scoy, Brian ^a   Brown, David ^a   Liu, Weiguo ^a   Bush, Karen ^c   Queenan, Anne Marie ^c   Morrow, Brian ^c   Khashab, Mohammed ^c   Kahn, James B ^c   Nicholson, Susan ^c   Kulawy, Robert ^a   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; IMIPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL KILLING; CONTROLLED STUDY; DRUG INFUSION; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLLOW FIBER; MINIMUM INHIBITORY CONCENTRATION; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TANDEM MASS SPECTROMETRY; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MUTATION; PORINS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 77952650628     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01721-09     Document Type: Article

References (10)

1. Chastre, J., R. Wunderink, P. Prokocimer, M. Lee, K. Kaniga, and I. Friedland. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36:1089-1096.
2. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
3. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl.):S42-S50.
4. Drusano, G. L., W. Liu, D. L. Brown, L. B. Rice, and A. Louie. 2009. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J. Infect. Dis. 199:219-226.
5. Hammami, S., R. Ghozzi, B. Burghoffer, G. Arlet, and S. Redjeb. 2009. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital. Pathol. Biol. (Paris) 57:530-535.
6. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48:3086-3092.
7. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
9. Tam, V. H., A. N. Schilling, S. Neshat, K. Poole, D. A. Melnick, and E. A. Coyle. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
10. Van Wart, S. A., D. R. Andes, P. G. Ambrose, and S. M. Bhavnani. 2009. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. Infect. Dis. 63:409-414.